Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05108558 · ClinicalTrials.gov registry record · Phase 4
Efficacy of a Novel CCH Protocol for PD Among Prior Non-responders
A Phase 4 study of Peyronie's Disease, sponsored by Charitable Union for the Research and Education of Peyronie's Disease.
- Active
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT05108558: Active Phase 4 study of Peyronie's Disease, sponsored by Charitable Union for the Research and Education of Peyronie's Disease.
NCT05108558 is a Phase 4 study of Peyronie's Disease that is active but no longer recruiting, run by Charitable Union for the Research and Education of Peyronie's Disease. The registered enrollment target is 40 participants, below the 182-participant average among 5 other Peyronie's Disease trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05108558, a Phase 4 study of Peyronie's Disease, is active but no longer recruiting, sponsored by Charitable Union for the Research and Education of Peyronie's Disease.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
Compare key clinical outcomes between controls and men treated with a novel CCH administration protocol among men previously unresponsive to CCH administration.
Primary Outcome
Compare the change in degree of penile curvature from baseline (using a goniometer) between control and treatment groups at 6 months
Conditions Studied
Interventions
- DEVICE RestoreX
- DRUG CCH administration
- DRUG Control - Crossover to CCH
Study Locations (1)
Utah
- The Male Fertility and Peyronie's Clinic - Orem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2021-09-20 |
| Est. Completion | 2028-09-20 |
| Phase | Phase 4 |
What the registry record for NCT05108558 still lists
NCT05108558 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 182-participant average among 5 other Peyronie's Disease trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Peyronie's Disease appearing as the primary indexed condition, and to 3 interventions - of which RestoreX is the first listed.
NCT05108558 reports a single indexed study location in Utah.
Frequently Asked Questions
What is clinical trial NCT05108558 about?
NCT05108558 is a clinical study titled "Efficacy of a Novel CCH Protocol for PD Among Prior Non-responders". Compare key clinical outcomes between controls and men treated with a novel CCH administration protocol among men previously unresponsive to CCH administration.
What is the current status of trial NCT05108558?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2021-09-20. Estimated completion is 2028-09-20.
What conditions does trial NCT05108558 study?
This clinical trial studies the following conditions: Peyronie's Disease.
What interventions are being tested in trial NCT05108558?
The interventions under investigation include: RestoreX (DEVICE), CCH administration (DRUG), Control - Crossover to CCH (DRUG).
Who is sponsoring clinical trial NCT05108558?
This trial is sponsored by Charitable Union for the Research and Education of Peyronie's Disease, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05108558 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peyronie's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Investigation of Surgery, Collagenase, and Restorex for the Improvement of Peyronie's
ACTIVE NOT RECRUITING · Phase 4
-
Study of AA4500 in the Treatment of Peyronie's Disease
COMPLETED · Phase 3
-
H-22411: BOTOX® for Peyronie's Disease
COMPLETED · Phase 2
-
Peyronie's Disease Treatment Protocol
COMPLETED · Phase 1
-
Study of AA4500 in the Treatment of Peyronie's Disease
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI